AKT1 and cardiac hypertrophy: The PI3K/Akt pathway is involved in cardiac remodeling, especially hypertrophic cardiomyopathy, via the mTOR pathway, and empagliflozin can suppress the cardiac hypertrophy caused by the PI3K/Akt/mTOR pathway (134).